These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34157320)

  • 1. Drug delivery to the inflamed intestinal mucosa - targeting technologies and human cell culture models for better therapies of IBD.
    Hartwig O; Shetab Boushehri MA; Shalaby KS; Loretz B; Lamprecht A; Lehr CM
    Adv Drug Deliv Rev; 2021 Aug; 175():113828. PubMed ID: 34157320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal enteroids/organoids: A novel platform for drug discovery in inflammatory bowel diseases.
    Yoo JH; Donowitz M
    World J Gastroenterol; 2019 Aug; 25(30):4125-4147. PubMed ID: 31435168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
    Yang C; Merlin D
    Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
    Pedersen G
    Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current pharmaceutical strategies for efficient site specific delivery in inflamed distal intestinal mucosa.
    Sharma S; Sinha VR
    J Control Release; 2018 Feb; 272():97-106. PubMed ID: 29317245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease.
    Zhang S; Ermann J; Succi MD; Zhou A; Hamilton MJ; Cao B; Korzenik JR; Glickman JN; Vemula PK; Glimcher LH; Traverso G; Langer R; Karp JM
    Sci Transl Med; 2015 Aug; 7(300):300ra128. PubMed ID: 26268315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Lehr CM; Fischer D; Stallmach A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):578-86. PubMed ID: 24084650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges.
    Nunes R; Neves JD; Sarmento B
    Nanomedicine (Lond); 2019 Oct; 14(19):2631-2644. PubMed ID: 31612773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease.
    Chen F; Liu Q; Xiong Y; Xu L
    Int J Nanomedicine; 2021; 16():4225-4237. PubMed ID: 34188471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease.
    Zhang Y; Thanou M; Vllasaliu D
    Eur J Pharm Biopharm; 2020 Oct; 155():128-138. PubMed ID: 32853696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients.
    Schmidt C; Lautenschlaeger C; Collnot EM; Schumann M; Bojarski C; Schulzke JD; Lehr CM; Stallmach A
    J Control Release; 2013 Jan; 165(2):139-45. PubMed ID: 23127508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa.
    Collnot EM; Ali H; Lehr CM
    J Control Release; 2012 Jul; 161(2):235-46. PubMed ID: 22306429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing polymer-derived drug delivery systems for combating inflammatory bowel disease.
    Pu Y; Fan X; Zhang Z; Guo Z; Pan Q; Gao W; Luo K; He B
    J Control Release; 2023 Feb; 354():1-18. PubMed ID: 36566845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
    Catalan-Serra I; Brenna Ø
    Hum Vaccin Immunother; 2018; 14(11):2597-2611. PubMed ID: 29624476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory pathways of importance for management of inflammatory bowel disease.
    Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH
    World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unleashing the Potential of Oral Deliverable Nanomedicine in the Treatment of Inflammatory Bowel Disease.
    Yang C; Sharma K; Mow RJ; Bolay E; Srinivasan A; Merlin D
    Cell Mol Gastroenterol Hepatol; 2024; 18(2):101333. PubMed ID: 38490294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymeric nanoparticles for the selective therapy of inflammatory bowel disease.
    Wachsmann P; Lamprecht A
    Methods Enzymol; 2012; 508():377-97. PubMed ID: 22449936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose Naltrexone for induction of remission in inflammatory bowel disease patients.
    Lie MRKL; van der Giessen J; Fuhler GM; de Lima A; Peppelenbosch MP; van der Ent C; van der Woude CJ
    J Transl Med; 2018 Mar; 16(1):55. PubMed ID: 29523156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the complex interactions between microbiota, host epithelial and immune cells in inflammatory bowel disease.
    Hirata Y; Ihara S; Koike K
    Pharmacol Res; 2016 Nov; 113(Pt A):574-584. PubMed ID: 27702681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug delivery strategies in the therapy of inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Fischer D; Stallmach A
    Adv Drug Deliv Rev; 2014 May; 71():58-76. PubMed ID: 24157534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.